Patent Issued for Compositions and methods for the treatment of depression (USPTO 12161622).

A patent has been issued for compositions and methods for treating major depressive disorder, particularly focusing on anhedonia, by administering aticaprant or a pharmaceutically acceptable salt thereof. The patent, assigned to Janssen Pharmaceuticals Inc., highlights the potential therapeutic benefits of Kappa opioid receptor antagonists in mood disorders. The inventors emphasize the need for effective treatments for patients with depression and anhedonia, especially those who have not responded adequately to other antidepressant therapies. [Extracted from the article]